BHST (BioHarvest Sciences) ROE %: -43.59% (As of Mar. 2026)


BHST BioHarvest Sciences Inc BHST
64 GF Score
Price $2.77
GF Value $8.57
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is BioHarvest Sciences ROE %?

BioHarvest Sciences BHST -1.42% 64 ROE % is -43.59% as of Mar. 2026. GuruFocus rates BHST with a GF Score™ of 64/100 and a GF Value™ of $8.57 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,916 Consumer Packaged Goods companies, BioHarvest Sciences ranks worse than 97.34% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. BioHarvest Sciences's annualized net income for the quarter that ended in Mar. 2026 was $-10.56 Mil. BioHarvest Sciences's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $24.24 Mil. Therefore, BioHarvest Sciences's annualized ROE % for the quarter that ended in Mar. 2026 was -43.59%.

The historical rank and industry rank for BioHarvest Sciences's ROE % or its related term are showing as below:

BHST' s ROE % Range Over the Past 10 Years
Min: -3509.64   Med: -443.28   Max: -83.17
Current: -111.9

During the past 12 years, BioHarvest Sciences's highest ROE % was -83.17%. The lowest was -3,509.64%. And the median was -443.28%.

BHST's ROE % is ranked worse than
97.34% of 1916 companies
in the Consumer Packaged Goods industry
Industry Median: 6.72 vs BHST: -111.90

BioHarvest Sciences  (NAS:BHST) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-10.564/24.2355
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-10.564 / 34.028)*(34.028 / 46.6115)*(46.6115 / 24.2355)
=Net Margin %*Asset Turnover*Equity Multiplier
=-31.05 %*0.73*1.9233
=ROA %*Equity Multiplier
=-22.67 %*1.9233
=-43.59 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-10.564/24.2355
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-10.564 / -10.38) * (-10.38 / -7.336) * (-7.336 / 34.028) * (34.028 / 46.6115) * (46.6115 / 24.2355)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0177 * 1.4149 * -21.56 % * 0.73 * 1.9233
=-43.59 %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


BioHarvest Sciences ROE % Related Terms


BioHarvest Sciences ROE % Historical Data

* Premium members only.

The historical data trend for BioHarvest Sciences's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioHarvest Sciences ROE % Chart

BioHarvest Sciences Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,509.64 0.00 0.00 0.00 -83.17

BioHarvest Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,119.82 0.00 -572.44 -53.14 -43.59

BHST vs GWLL, CLNN, FTLF: ROE % Comparison

For the Packaged Foods subindustry, BioHarvest Sciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioHarvest Sciences ROE % vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, BioHarvest Sciences's ROE % distribution charts can be found below:

* The bar in red indicates where BioHarvest Sciences's ROE % falls into.


BHST
64GF Score
BioHarvest Sciences Inc BHST
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioHarvest Sciences ROE % Calculation

BioHarvest Sciences's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=-11.135/( (1.33+25.448)/ 2 )
=-11.135/13.389
=-83.17 %

BioHarvest Sciences's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=-10.564/( (25.448+23.023)/ 2 )
=-10.564/24.2355
=-43.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of -43.59% mean?
BioHarvest Sciences (BHST) has a ROE % of -43.59% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on BioHarvest Sciences and its competitors. According to the industry distribution chart, BioHarvest Sciences ranks #1865 out of 1916 companies in the Consumer Packaged Goods industry, placing it in the top 97.3%.
Is BioHarvest Sciences' ROE % too high?
BioHarvest Sciences' current ROE % is -43.59%. Based on the distribution chart, BioHarvest Sciences ranks #1865 out of 1916 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, BioHarvest Sciences has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioHarvest Sciences' ROE % compare to GWLL and CLNN?
According to the Consumer Packaged Goods industry distribution chart, BioHarvest Sciences ranks #1865 out of 1916 companies for ROE %. This places BioHarvest Sciences in the lower half of its industry. The industry median ROE % is 6.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Consumer Packaged Goods company?
The median ROE % among Consumer Packaged Goods companies is 6.72, based on 1,916 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on BioHarvest Sciences and its competitors. For the Consumer Packaged Goods industry, the median ROE % is 6.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioHarvest Sciences's current ROE % is -43.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioHarvest Sciences stock overvalued right now?
Based on GuruFocus' analysis, BioHarvest Sciences (BHST) is currently considered Possible Value Trap. The stock's GF Value™ is $8.57, compared to a current price of $2.77 — trading 67.7% below its estimated fair value. The current ROE % is -43.59%. BioHarvest Sciences' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For BioHarvest Sciences (BHST), the current ROE % is -43.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioHarvest Sciences (BHST) Overvalued in 2026?

Based on GuruFocus' analysis, BioHarvest Sciences stock appears to be undervalued. The current stock price of $2.77 is trading 67.7% below its estimated GF Value™ of $8.57. GuruFocus considers BioHarvest Sciences to be Possible Value Trap.

Key valuation signals for BHST:

  • ROE %: -43.59%
  • GF Value™: $8.57 vs. price of $2.77 (67.7% below fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the BHST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioHarvest Sciences Business Description

Other Exchanges 8MV0:Germany
Address 1140-625 Howe Street, Vancouver, BC, CAN, V6C 2T6
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
64GF Score

Get the complete analysis for BHST

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.77
Price
$8.57
GF Value